Literature DB >> 7901887

Variation in the serum IgA concentration and the production of IgA in vitro in rheumatoid arthritis treated by sulfasalazine.

C Jorgensen1, C Bologna, J M Anaya, T Reme, J Sany.   

Abstract

Sulfasalazine is an efficient treatment for rheumatoid arthritis (RA), but its mode of action is not known. In RA, a correlation has been demonstrated between disease activity and the secretion of immunoglobulin A (IgA) by peripheral blood lymphocytes (PBL) in culture. Furthermore, the IgA-producing cells of the peripheral blood have been shown to originate from the mucous-associate lymphoid tissue (MALT). We studied the variations in the total IgA concentration in the serum of RA patients, and the secretion of IgA by PBL after 7 days culture in vitro, before and after treatment with sulfasalazine. A significant decrease in the serum IgA concentration was obtained, but there was no modification of the spontaneous increase in the in vitro IgA synthesis by circulating mononuclear cells. Our results suggested that the decrease in serum IgA concentration after treatment with sulfasalazine was not linked to a decrease in the IgA secretion by PBL. This does not favour a direct effect of sulfasalazine on the mucous-associated lymphoid tissue.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901887     DOI: 10.1007/bf00290298

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  17 in total

1.  Enumeration of IgA producing cells by the enzyme linked immunospot (ELISPOT) technique to evaluate sulphasalazine effects in inflammatory arthritides.

Authors:  N Feltelius; S Gudmundsson; L Wennersten; O Sjöberg; R Hällgren; L Klareskog
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

2.  IgA related disorders in rheumatoid arthritis.

Authors:  S R Pillemer; W J Reynolds; S J Yoon; M Perera; M Newkirk; M Klein
Journal:  J Rheumatol       Date:  1987-10       Impact factor: 4.666

3.  Serum IgA, acute phase proteins, and glycosylation of alpha 1-acid glycoprotein in ankylosing spondylitis.

Authors:  A Mackiewicz; M A Khan; T L Reynolds; S van der Linden; I Kushner
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

Review 4.  Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response.

Authors:  J Mestecky; J R McGhee
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

5.  [Renal microscopic hematuria in rheumatoid polyarthritis].

Authors:  A Cantagrel; B Fournie; J Pourrat; J J Conte; A Fournie
Journal:  Rev Med Interne       Date:  1991 Jan-Feb       Impact factor: 0.728

6.  Characterisation of the size and composition of circulating immune complexes in patients with rheumatoid arthritis.

Authors:  R A Mageed; J R Kirwan; P W Thompson; D A McCarthy; E J Holborow
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

7.  Immunological comparison of patients with rheumatoid arthritis with and without nephropathy.

Authors:  M Korpela; J Mustonen; H Helin; A Pasternack
Journal:  Ann Rheum Dis       Date:  1990-04       Impact factor: 19.103

8.  Haematuria in rheumatoid arthritis: an association with mesangial glomerulonephritis.

Authors:  L D Hordon; L Sellars; A R Morley; R Wilkinson; M Thompson; I D Griffiths
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

9.  Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate.

Authors:  D E Bax; R S Amos
Journal:  Ann Rheum Dis       Date:  1985-03       Impact factor: 19.103

10.  Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis.

Authors:  D P Symmons; M Salmon; M Farr; P A Bacon
Journal:  J Rheumatol       Date:  1988-04       Impact factor: 4.666

View more
  1 in total

Review 1.  Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.

Authors:  C P Rains; S Noble; D Faulds
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.